SCHEMBL702004

SCHEMBL702004

O=CN[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 8/20 0.57
NAALAD2 Q9Y3Q0 3/20 0.57
RIMKLA Q8IXN7 1/20 0.57
GGH Q92820 1/20 0.48
TET2 Q6N021 3/20 0.43
KDM4A O75164 2/20 0.43
KDM4C Q9H3R0 2/20 0.43
KDM2A Q9Y2K7 2/20 0.43
TET3 O43151 1/20 0.43
CYP1A2 P05177 2/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GSR P00390 1/20 0.41
GRIK1 P39086 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15935963 1.00 FOLH1 (0.57) FOLH1NAALAD2RIMKLAGGHTET2
SCHEMBL702003 1.00 FOLH1 (0.57) FOLH1NAALAD2RIMKLAGGHTET2
SCHEMBL28883926 0.98 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGGHTET2
SCHEMBL10699563 0.86 FOLH1 (0.45) FOLH1NAALAD2RIMKLA
SCHEMBL18583123 0.84 LMNA (0.44) FOLH1NAALAD2RIMKLA
Aniline SCHEMBL27955361 0.83 NAALAD2 (0.48) FOLH1NAALAD2RIMKLAGGH
Aniline SCHEMBL27955360 0.83 NAALAD2 (0.48) FOLH1NAALAD2RIMKLAGGH
SCHEMBL7046561 0.83 KMT2A (0.47) FOLH1NAALAD2RIMKLAGGH
SCHEMBL2920459 0.83 KMT2A (0.47) FOLH1NAALAD2RIMKLAGGH
SCHEMBL2923058 0.83 FOLH1 (0.44) FOLH1NAALAD2RIMKLAGGHTET2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230405091-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP ASSETS B.V. (NL) 2023-12-21 US claimed
EP-4228424-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP Assets B.V. (NL) 2023-08-23 EP claimed
CN-116390651-A Methods of modulating gastrointestinal metabolites 帝斯曼知识产权资产管理有限公司 2023-07-04 CN claimed
US-20230200412-A1 METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES DSM IP ASSETS B.V. (NL) 2023-06-29 US claimed
CN-116267786-A Method for improving summer synchronous estrus-timing insemination effect of buffalo 安徽科技学院 2023-06-23 CN claimed
EP-4118090-A1 METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES DSM IP Assets B.V. (NL) 2023-01-18 EP claimed
CN-115551873-A Methods for modulating gastrointestinal microbial metabolic pathways and metabolites 帝斯曼知识产权资产管理有限公司 2022-12-30 CN claimed
WO-2022079238-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP ASSETS B.V. (NL) 2022-04-21 WO claimed
WO-2021183896-A1 METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES DSM IP ASSETS, B.V. (NL) 2021-09-16 WO claimed
CN-110368132-B Treatment method for improving synchronous estrus-timing insemination effect of dairy cows in summer 华中农业大学 2020-09-15 CN claimed
EP-1974047-B1 PROCESS FOR REGIOSELECTIVE N(5)-FORMYLATION OF (6S)-5,6,7,8-TETRAHYDRO-PTEROIC ACID AND DERIVATIVES THEREOF CERBIOS PHARMA SA (CH) 2010-09-01 EP claimed
EP-1974047-A2 PROCESS FOR REGIOSELECTIVE N(5)-FORMYLATION OF (6S)-5,6,7,8-TETRAHYDRO-PTEROIC ACID AND DERIVATIVES THEREOF Cerbios-Pharma S.A. (CH) 2008-10-01 EP claimed
WO-2007082402-A2 PROCESS FOR REGIOSELECTIVE N(5)-FORMYLATION OF (6S)-5,6,7,8-TETRAHYDROPTEROIC ACID AND DERIVATIVES THEREOF CERBIOS-PHARMA S.A. (CH) 2007-07-26 WO claimed
CN-121428037-A Method for synthesizing levofolinic acid based on enzymatic tandem reaction 浙江工业大学 2026-01-30 CN disclosed
US-12534439-B2 Xanthohumol derivatives and methods for making and using OREGON STATE UNIVERSITY (US) 2026-01-27 US disclosed
CN-119343061-A Pharmaceutical and nutraceutical compositions containing amino acid combinations and their use in diseases characterized by lipid accumulation in tissues 欧罗卡特基金会 2025-01-21 CN disclosed
CN-1032858-C Methylamino pterin derivatives CHUGAI PHARMACEUTICAL CO LTD (JP) 1996-09-25 CN disclosed
CN-1059725-A Novel methotrexate derivatives CHUGAI PHARMACEUTICAL CO LTD (JP) 1992-03-25 CN disclosed
EP-0388456-A1 8,10-DIDEAZATETRAHYDROFOLIC ACID DERIVATIVES SRI INTERNATIONAL (US) 1990-09-26 EP disclosed
WO-1990002745-A1 8,10-DIDEAZATETRAHYDROFOLIC ACID DERIVATIVES SRI INTERNATIONAL (US) 1990-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534439-B2 Xanthohumol derivatives and methods for making and using MT-CO1, MT-CO2, PC FOLH1 3243/4885NAALAD2 4441/4885RIMKLA 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.